olanzapine · Cheplapharm · NDA 020592, 021253
Zyprexa
Earliest generic entry, as listed · earliest of 7 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 219048, Omnivium Pharms · 021253-001Approved 23 Jan 2026Detected 25 Oct 2026Historical import
- Generic approved · ANDA 220323, Adaptis · 021253-001Approved 5 Mar 2026Detected 25 Oct 2026Historical import
Products covered · 7
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020592 · 001 · RLD | tablet, oral | 2.5MG | open |
| 020592 · 002 · RLD | tablet, oral | 5MG | open |
| 020592 · 003 · RLD | tablet, oral | 7.5MG | open |
| 020592 · 004 · RLD | tablet, oral | 10MG | open |
| 020592 · 005 · RLD | tablet, oral | 15MG | open |
| 020592 · 006 · RLD | tablet, oral | 20MG | open |
| 021253 · 001 · RLD | powder, intramuscular | 10MG/VIAL | open |